Last reviewed · How we verify
Jenzyl (RIDAFOROLIMUS)
Jenzyl blocks the mTOR pathway, which is a key regulator of cell growth and division.
Jenzyl (Ridaforolimus) is a small molecule inhibitor of the serine/threonine-protein kinase mTOR. It works by blocking the mTOR pathway, which is involved in cell growth and proliferation. Jenzyl is used to treat certain types of cancer, but its commercial status is unknown. The drug has a half-life of 46.3 hours, but its bioavailability and patent status are not publicly available. As a result, its availability as a generic medication is also unknown.
At a glance
| Generic name | RIDAFOROLIMUS |
|---|---|
| Drug class | ridaforolimus |
| Target | Dual specificity tyrosine-phosphorylation-regulated kinase 1B, Serine/threonine-protein kinase mTOR |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Mechanism of action
Think of the mTOR pathway like a traffic light for cell growth. When mTOR is active, it's like the light is green, and the cell can grow and divide. Jenzyl works by flipping the light to red, stopping the cell from growing and dividing out of control.
Approved indications
Common side effects
Key clinical trials
- IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (NA)
- First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease (NA)
- IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (NA)
- BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
- Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) (PHASE1)
- Study of BioNIR Drug Eluting Stent System in Coronary Stenosis (NA)
- MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (NA)
- Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jenzyl CI brief — competitive landscape report
- Jenzyl updates RSS · CI watch RSS